Tafamidis

Department of Health and Social Care written question – answered on 16th December 2021.

Alert me about debates like this

Photo of Apsana Begum Apsana Begum Labour, Poplar and Limehouse

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to make Tafamadis, the only treatment for the terminal illness hereditary cardiac Amyloidosis, available to UK families.

Photo of Apsana Begum Apsana Begum Labour, Poplar and Limehouse

To ask the Secretary of State for Health and Social Care, what the timetable is for Tafamadis to be made available on the NHS for people with hereditary cardiac amyloidosis.

Photo of Edward Argar Edward Argar Minister of State (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded based on an assessment of their clinical and cost effectiveness. NICE published guidance in May 2021 that does not recommend tafamidis for the treatment of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults. NHS England and NHS Improvement do not therefore routinely commission tafamidis for NHS patients in England. Where a treatment is not routinely commissioned by the NHS, a patient’s clinician may submit an individual funding request if they consider it is in their patient’s best interests to have that treatment.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.